No Data
No Data
How Is The Market Feeling About Exact Sciences?
Exact Sciences's (NYSE:EXAS) short percent of float has fallen 4.32% since its last report. The company recently reported that it has 8.50 million shares sold short, which is 4.65% of all regular shar
Exact Sciences (EXAS) Witnesses Rising Expenses, Competition
When Will Exact Sciences Corporation (NASDAQ:EXAS) Turn A Profit?
We feel now is a pretty good time to analyse Exact Sciences Corporation's (NASDAQ:EXAS) business as it appears the company may be on the cusp of a considerable accomplishment. Exact Sciences Corpora
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences to Participate in June Investor Conferences
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate
Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok -- WSJ
By Peter Loftus Shares of Guardant Health were up 8% Friday morning after an advisory panel to the U.S. Food and Drug Administration endorsed the companys blood test to detect colorectal cancer. A s
No Data